Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity [Yahoo! Finance]
Artiva Biotherapeutics, Inc. (ARTV)
Company Research
Source: Yahoo! Finance
The US company outlaid 20,125,000 shares of its common stock at a public offering price of $18 per share, including a further 2,625,000 shares issued for underwriters, as per a 16 September press release, offering a sign of positivity to an undulating biotech listing sector. Bicara hit the Nasdaq trading boards under the ticker ‘BCAX' on Friday last week, where its shares opened at $26.25 – representing a 31% premium on the offer price. The stocks have dropped very slightly, settling at $25.41 at close on 16 September. Bicara twice upsized its IPO in recent weeks to bring in funds for a pivotal Phase II/III clinical trial of lead asset ficerafusp alfa in head and neck squamous cell carcinoma. Two other drug developers, Zenas BioPharma and MBX Biosciences, also debuted on Nasdaq last week, marking a flurry of activity in an otherwise quiet biotech IPO landscape. Autoimmune specialist Zenas raised $225m while MBX, which is investigating candidates in endocrine and metabolic indic
Show less
Read more
Impact Snapshot
Event Time:
ARTV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARTV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARTV alerts
High impacting Artiva Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ARTV
News
- Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $23.00 price target on the stock.MarketBeat
- Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewswire
- Artiva Biotherapeutics to Participate in the Jefferies London Healthcare ConferenceGlobeNewswire
- Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of DirectorsGlobeNewswire
- Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare ConferenceGlobeNewswire
ARTV
Sec Filings
- 11/14/24 - Form SC
- 11/12/24 - Form 10-Q
- 11/12/24 - Form 8-K
- ARTV's page on the SEC website